971 related articles for article (PubMed ID: 17543777)
1. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
2. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant de novo malignancies in renal transplant recipients: the past and present.
Kauffman HM; Cherikh WS; McBride MA; Cheng Y; Hanto DW
Transpl Int; 2006 Aug; 19(8):607-20. PubMed ID: 16827677
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
5. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
Andrés V; Castro C; Campistol JM
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
[TBL] [Abstract][Full Text] [Related]
6. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.
Epailly E; Albanell J; Andreassen A; Bara C; Campistol JM; Delgado JF; Eisen H; Fiane AE; Mohacsi P; Schubert S; Sebbag L; Turazza FM; Valantine H; Zuckermann A; Potena L
Clin Transplant; 2011; 25(5):E475-86. PubMed ID: 21592231
[TBL] [Abstract][Full Text] [Related]
7. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
8. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
de Fijter JW
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
10. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
Campistol JM; Schena FP
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
Zuckermann A; Manito N; Epailly E; Fiane A; Bara C; Delgado JF; Lehmkuhl H; Ross H; Eisen H; Chapman J; Valantine H
J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
[TBL] [Abstract][Full Text] [Related]
12. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin inhibitors in heart transplantation.
Keogh A
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
Gaumann A; Schlitt HJ; Geissler EK
Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
[TBL] [Abstract][Full Text] [Related]
15. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Valantine H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
[TBL] [Abstract][Full Text] [Related]
16. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
17. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Kahan BD
Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
[TBL] [Abstract][Full Text] [Related]
18. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Geissler EK
Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
[TBL] [Abstract][Full Text] [Related]
19. Cancers after renal transplantation.
Wong G; Chapman JR
Transplant Rev (Orlando); 2008 Apr; 22(2):141-9. PubMed ID: 18631867
[TBL] [Abstract][Full Text] [Related]
20. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
